Furthermore, the molecular docking results presented the stable and high-affinity binding of NGR1 to TNF-α, IL-6, MMP3, MMP9, and MMP13, indicating that NGR1 may exert its therapeutic effects on tendinopathy by modulating inflammatory responses and cellular and extracellular matrix metabolism. Here, MMP9 is linked to disease of the tendon.